Creating a new generation of safe cognitive medicine


Arcadia Medicine is developing safer and more effective drug-assisted mental health therapies

Arcadia was founded in 2020 to bring safe empathogens to market and transform the mental health therapeutics space

It has since built a pipeline to develop a portfolio of safer and more effective CNS compounds with a highly experienced team of scientists, engineers, and regulators

A better form of MDMA

A non-racemic, non-neurotoxic form of MDMA with an improved therapeutic profile.

Safer with fewer
side effects

A non-racemic, non-neurotoxic form of MDMA, with an improved therapeutic profile

Wider therapeutic window

Wider range of effective doses, enables more precise therapy and improved safety parameters

Engineered for
optimal effect

Higher selectivity for serotonin and oxytocin release, increasing therapeutic effect

Our
Pipeline

Arcadia Medicine is advancing a pipeline of promising therapeutic candidates designed to address mental health disorders that were previously intractable or inadequately addressed with existing psychedelic medicine

Drug

In Development

Preclinical

Phase I/II

Phase III

AM-1002

PTSD (Post-Traumatic Stress Disorder)

A non-racemic, non-neurotoxic form of MDMA with an improved therapeutic profile.

AM-1004

MDD (Major Depressive Disorder)

A short-acting psychoactive-empathogen combination therapy with an improved therapeutic profile.

AM-1006

SA (Substance Abuse)

A subperceptual psychoactive product designed to produce a short acting effect for optimized use in a traditional hour-long therapeutic setting

Our Pipeline

Arcadia Medicine is advancing a pipeline of promising therapeutic candidates designed to address mental health disorders that were previously intractable or inadequately addressed with existing therapeutics

PRECLINICAL

AM-1002

PTSD (Post-Traumatic Stress Disorder)

A non-racemic, non-neurotoxic form of MDMA with an improved therapeutic profile.

IN DEVELOPMENT

AM-1004

MDD (Major Depressive Disorder)

A short-acting psychoactive-empathogen combination therapy with an improved therapeutic profile

IN DEVELOPMENT

AM-1006

SA (Substance Abuse)

A subperceptual psychoactive product designed to produce a short acting effect for optimized use in a traditional hour-long therapeutic setting

Discovery Platform

Predict

Arcadia’s pharmacological model identifies optimal drug pharmacology profiles based on relevant receptor affinity, enantioselective metabolic profile, and existing safety and tolerance data.

Select

Top candidates and combinations are evaluated based on their pharmacology, pharmacokinetics, and half-life to optimize expected safety and efficacy.

Learn

Our model generates extensive datasets, which are used to continuously curate and refine the prediction process, both before and during preclinical evaluation.

Team

Chief Executive Officer and Founder

Nikita Obidin

Vice President of Regulatory Affairs

GARY RIORDAN

Chief of Staff

JACLYN CHAU

Head of Strategy and Operations

Serena Lim-strutt

Core CMC Partner

JOan connolly

Advisors

Scientific Advisor

Boris Heifets

Scientific Advisor

Graham Pechenik

Strategic advisor

Josh Hardman

Strategic Advisor

JAMIE HEYWOOD

Strategic Advisor

QUINTIN FRERICHS

Strategic Advisor

Sarah Sclarsic

Investors

Contact Us

Name

ADDRESS

2261 Market Street, #4519 San Francisco, CA, 94114

EMAIL